ZS Pharma, a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced that data from a pivotal Phase 3 trial of ZS-9, an investigational treatment for hyperkalemia, will be presented as a late-breaking clinical trial oral presentation at the National Kidney Foundation’s 2014 Spring Clinical Meetings in Las Vegas.
Help employers find you! Check out all the jobs and post your resume.
